136 related articles for article (PubMed ID: 16167021)
21. Five important advances in hematopathology.
Shi M; Xiao R; Woda BA; Yu H
Arch Pathol Lab Med; 2014 Mar; 138(3):410-9. PubMed ID: 24576034
[TBL] [Abstract][Full Text] [Related]
22. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
[No Abstract] [Full Text] [Related]
23. Different lineage involvement in myelodysplastic/myeloproliferative disease with combined MPLW515L and JAK2V617F mutation.
Hussein K; Theophile K; Buhr T; Beller A; Kreipe H; Bock O
Br J Haematol; 2009 Jun; 145(5):673-5. PubMed ID: 19344408
[No Abstract] [Full Text] [Related]
24. Cutaneous extramedullary hemopoiesis in chronic myeloproliferative and myelodysplastic disorders.
Haniffa MA; Wilkins BS; Blasdale C; Simpson NB
J Am Acad Dermatol; 2006 Aug; 55(2 Suppl):S28-31. PubMed ID: 16843120
[TBL] [Abstract][Full Text] [Related]
25. [Some new findings in the pathogenesis of myeloproliferative disorders and new insight into more effective treatment].
Klener P
Cas Lek Cesk; 2006; 145(1):4-8. PubMed ID: 16468234
[TBL] [Abstract][Full Text] [Related]
26. Myelodysplastic/myeloproliferative neoplasms: a disease in need of recognition.
Khan M; Sarfraz M; Daver N
Future Oncol; 2017 Jan; 13(2):117-120. PubMed ID: 27676208
[No Abstract] [Full Text] [Related]
27. Clonal chromosome anomalies and propensity to myeloid malignancies in congenital amegakaryocytic thrombocytopenia (OMIM 604498).
Maserati E; Panarello C; Morerio C; Valli R; Pressato B; Patitucci F; Tassano E; Di Cesare-Merlone A; Cugno C; Balduini CL; Lo Curto F; Dufour C; Locatelli F; Pasquali F
Haematologica; 2008 Aug; 93(8):1271-3. PubMed ID: 18519517
[No Abstract] [Full Text] [Related]
28. Myelodysplastic and myeloproliferative disorders in children.
Hasle H
Curr Opin Pediatr; 2007 Feb; 19(1):1-8. PubMed ID: 17224655
[TBL] [Abstract][Full Text] [Related]
29. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.
Haferlach C; Rieder H; Lillington DM; Dastugue N; Hagemeijer A; Harbott J; Stilgenbauer S; Knuutila S; Johansson B; Fonatsch C
Genes Chromosomes Cancer; 2007 May; 46(5):494-9. PubMed ID: 17311250
[TBL] [Abstract][Full Text] [Related]
30. p38 mitogen-activated protein kinase has different degrees of activation in myeloproliferative disorders and myelodysplastic syndromes.
Shahjahan M; Dunphy CH; Ewton A; Zu Y; Monzon FA; Rice L; Chang CC
Am J Clin Pathol; 2008 Oct; 130(4):635-41. PubMed ID: 18794058
[TBL] [Abstract][Full Text] [Related]
31. Acquired somatic variants in inherited myeloid malignancies.
Armes H; Rio-Machin A; Krizsán S; Bödör C; Kaya F; Bewicke-Copley F; Alnajar J; Walne A; Péterffy B; Tummala H; Rouault-Pierre K; Dokal I; Vulliamy T; Fitzgibbon J
Leukemia; 2022 May; 36(5):1377-1381. PubMed ID: 35140362
[No Abstract] [Full Text] [Related]
32. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
33. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.
Niemeyer CM; Kratz CP
Br J Haematol; 2008 Mar; 140(6):610-24. PubMed ID: 18302710
[TBL] [Abstract][Full Text] [Related]
34. [Bioptic medullary findings for the formation of fibres in attended and not yet attended myeloses (author's transl)].
Hill K; Dennhardt HH
Verh Dtsch Ges Pathol; 1972; 56():587-92. PubMed ID: 4130904
[No Abstract] [Full Text] [Related]
35. A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease.
Loscocco GG; Mannelli F; Mannelli L; Vergoni F; Gesullo F; Rotunno G; Guglielmelli P; Vannucchi AM
Am J Hematol; 2020 Dec; 95(12):1622-1624. PubMed ID: 32242958
[No Abstract] [Full Text] [Related]
36. Fluorescence in situ hybridization reveals closely correlated results in cytological and histological specimens of hematological neoplasias compared to conventional cytogenetics.
Gerr H; Gadzicki D; Kreipe H; Schlegelberger B; Wilkens L
Pathobiology; 2006; 73(6):271-9. PubMed ID: 17374964
[TBL] [Abstract][Full Text] [Related]
37. Progenitor cells and classification of myelodysplastic and myeloproliferative disorders.
Brown G; Bunce CM; Rose PE; Howie AJ
Lancet; 1985 Oct; 2(8460):885. PubMed ID: 2864593
[No Abstract] [Full Text] [Related]
38. [Reduction of Ph1 chromosome in atypical myeloproliferative disorder by intensive chemotherapy].
Takeyama H; Yano K; Fukutani H; Yamamoto F; Watanabe E; Satake T
Rinsho Ketsueki; 1986 Sep; 27(9):1640-4. PubMed ID: 3468279
[No Abstract] [Full Text] [Related]
39. Introduction to 'Spotlight on myeloproliferative neoplasms'.
Muller-Berat Killmann CN
Leukemia; 2008 Jan; 22(1):2. PubMed ID: 18197172
[No Abstract] [Full Text] [Related]
40. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.
Oki Y; Jelinek J; Beran M; Verstovsek S; Kantarjian HM; Issa JP
Haematologica; 2006 Aug; 91(8):1147-8. PubMed ID: 16870548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
